Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of adMare BioInnovations.

    Client Virtual Booth

    ADMARE BIOINNOVATIONS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    adMare BioInnovations
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    2405 Wesbrook Mall, 4th Floor Vancouver, British Columbia Canada V6T 1Z3
    Telephone
    Telephone
    604.827.1147
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.admarebio.com/en/
    Linkedin
    Linkedin
    https://ca.linkedin.com/company/admare-bioinnovations
    Twitter
    Twitter
    https://twitter.com/adMare_Bio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AdMare and AazeinTx Inc. Sign Global Exclusive Agreement for Promising Acute Asthma Treatment (NEO6860)

    Details:

    AazeinTx has acquired all rights to NEO6860, a clinical-stage TRPV1 antagonist in adMare’s technology portfolio. With a team at the University of Calgary led by Dr. Richard Wilson AazeinTx proposes to bring a pill-based form of NEO6860.


    Lead Product(s): NEO6860

    Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NEO6860

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: AazeinTX

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 17, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations

    Details:

    The parties have terminated the 2017 license agreement pursuant to which the Company had exclusive rights to develop and commercialize the BLU-5937 Assets and henceforth.


    Lead Product(s): BLU-5937

    Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: BELLUS Health

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement March 23, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search